phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma
Published 8 years ago • 352 plays • Length 2:15Download video MP4
Download video MP3
Similar videos
-
2:14
lux-lung 7: phase 2b trial of first-line afatinib versus gefitinib for egfr mutation-positive nsclc
-
1:21
lux-lung 7: phase 2b trial of afatinib versus gefitinib for egfr-mutated lung cancer in first-line
-
4:56
active trial update: egfrm nsclc
-
1:31
lux-lung 7: phase 2b trial of afatinib versus gefitinib for egfr-mutated adenocarcinoma of the lung
-
5:59
targeted therapy in consolidation setting for lung cancer
-
0:56
belief: phase 2 trial of erlotinib plus bevacizumab for non-small cell lung cancer
-
5:01
chemotherapy-tki combinations in metastatic egfr lung cancer
-
2:16
dr. rotow on results of a phase 1/2 trial with osimertinib/gefitinib in egfr-mutant nsclc
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
9:57
clinical trials for small cell lung cancer - highlights: lung cancer living room
-
7:16
checkmate 9la study: nivo ipi in nsclc
-
2:12
phase 1 study of anti-pd-l1 durvalumab plus gefitinib in tki-naïve patients with egfr-mutant nsclc
-
11:13
gracecast-091_lung-cancer_highlights 2011: the egfr axis
-
6:08
flaura study: a new standard of care for patients with egfr mutated nsclc
-
7:38
immunotherapy/chemo triplet in frontline nsclc
-
3:08
choosing immunotherapy as front line therapy for non-actionable nsclc
-
3:48
poseidon: durvalumab /- tremelimumab chemo in 1l mnsclc
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
40:44
gracecast-050_lung-cancer_ramalingam on first line therapy for advanced nsclc